Marica Vaapil

Senior Research Scientist at BioInvent International

Marica Vaapil has a diverse work experience in the field of research. Marica is currently working as a Research Scientist at BioInvent International AB since January 2021. Prior to this, they worked as a Researcher at Lund University in 2017. Marica also has experience as a Postdoctoral Researcher at Berkeley Lab from May 2015 to December 2016. At Lund University, they worked as a Cancer Researcher and a PhD student in Medical Science, specializing in breast cancer and small cell lung carcinoma. Their research focused on tumor microenvironment, hypoxia, cell differentiation, and proliferation.

Marica Vaapil's education journey began in 2001 when they enrolled in Karolinska Institutet to pursue the study of Chemistry and Nutritional Physiology. Marica completed this course in 2002.

The following year, in 2002, Marica Vaapil joined Arkansas State University, where they pursued a Bachelor of Arts in Science with a major in Chemistry and a minor in Biology. This program spanned from 2002 to 2005.

Continuing their academic pursuits, Marica Vaapil enrolled at Lund University in 2006 to pursue a Master of Science degree in Molecular Genetics. Marica completed this two-year program in 2008.

Building on their foundation of knowledge, Marica Vaapil went on to pursue a Ph.D. in Medical Science at Lund University. Their doctoral studies focused on Molecular Medicine and Tumor Biology. Marica began this five-year program in 2009 and successfully completed it in 2014.

Overall, Marica Vaapil has a diverse educational background, ranging from Chemistry and Biology to Molecular Genetics, Molecular Medicine, and Tumor Biology. Their academic journey has taken their through multiple institutions, allowing their to gain expertise in various disciplines.

Location

Malmö, Sweden

Links


Org chart

No direct reports

Teams


Offices

This person is not in any offices


BioInvent International

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.


Industries

Headquarters

Lund, Sweden

Employees

51-200

Links